™
ONCE-
DAILY
DOSING
1,2,5
™
OPTIMAL
HbA
1C
CONTROL
1-4
™
LESS
WEIGHT
GAIN
2,3
™
LOW
RISK OF
HYPOS
2,4
™
FlexPen
®
TRUSTED BY
MILLIONS
6
No other basal insulin can offer you more
References
1.
Blonde L et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE™ study. Diabet. Obes. and Metab.
2009;11:623–631.
2.
Philis-Tsimikas A et al. Comparison of Once-Daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes. Clin Ther 2006;28(10):1569–1581.
3.
Rosenstock J et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia
2008;51:408–416.
4.
Hermansen K et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People with Type 2
Diabetes. Diabetes Care 2006;29(6):1269–1274.
5.
Klein O et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabet. Obes.
and Metab. 2007;9:290–299.
6.
World IMS Data, September 2009.
Proprietary Name:
Levemir
®
.
Scheduling Status:
S3
Composition:
Insulin detemir 100 units /ml.
Indication:
Treatment of insulin requiring patientswithdiabetesmellitus.
RegistrationNumber:
38/21.1/0084. For full prescribing
information refer to package insert approved by the medicines regulatory authority.
Novo Nordisk (Pty) Ltd. Reg No. 1959/000833/07. PO Box 783155, Sandton 2146. Tel: (011) 202 0500 Fax: (011) 807 7989
NN/DUO3817/02/2010ver1
